

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 June 2000 (22.06.2000)

PCT

(10) International Publication Number  
WO 00/036092 A3

(51) International Patent Classification<sup>7</sup>: C12N 5/10, 1/19,  
1/21, C07K 19/00, A61K 38/00 // C07K 14/705, 14/525

(21) International Application Number: PCT/US99/29873

(22) International Filing Date:  
16 December 1999 (16.12.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/112,752 17 December 1998 (17.12.1998) US

(71) Applicant (for all designated States except US): BIO-  
GEN, INC. [US/US]; 14 Cambridge Center, Cambridge,  
MA 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BROWNING,  
Jeffrey [US/US]; 32 Milton Road, Brookline, MA 02146  
(US). MIATKOWSKI, Konrad [PL/US]; 2 Bradley  
Street, North Reading, MA 01864 (US). MEIER, Werner  
[CH/US]; 31 Bedford Street, Burlington, MA 01803 (US).

(74) Agent: FLYNN, Kerry, A.; Biogen, Inc., 14 Cambridge  
Center, Cambridge, MA 02142 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
23 November 2000

(48) Date of publication of this corrected version:  
22 August 2002

(15) Information about Correction:  
see PCT Gazette No. 34/2002 of 22 August 2002, Section  
II

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN- $\beta$  RECEPTOR IMMUNOGLOB-  
ULIN CHIMERIC PROTEINS AND THEIR PURIFICATION

(57) Abstract: The invention relates to methods for the expression of high yields of the form protein-immunoglobulin fusions having high affinity binding to its ligand, by culturing hosts transformed with DNA encoding the desired fusions in a culture system at a low temperature thereby minimizing the amount of misfolded or misbridged protein forms. Said host cells may be transformed mammalian, insect, yeast or bacterial cells. The protein-immunoglobulin fusion may comprises a member of the TNF or TNF-receptor family, such as lymphotoxin-beta or lymphotoxin-beta receptor. The invention also relates to pharmaceutical composition comprising said protein-immunoglobulin fusions.



WO 00/036092 A3

Method for the High Level Expression of Active Lymphotoxin- $\beta$  Receptor  
Immunoglobulin Chimeric Proteins and Their Purification

BACKGROUND

The TNF family consists of pairs of ligands and their specific receptors referred  
5 to as TNF family ligands and TNF family receptors (Bazzoni and Beutler, 1996;  
Aggarwal and Natarajan, 1996). The ligands such as TNF are typically found as  
membrane bound forms on cell surfaces, or in some cases they are selectively cleaved  
from the cell surface and secreted. The ligands bind to specific receptors and the  
binding event serves to aggregate two or more receptors. The intracellular domains of  
10 these receptors can in some way sense this change and communicate this information  
into the cell via a signal transduction mechanism. The family is involved in the  
regulation of the immune system and possibly other non-immunological systems. The  
regulation is often at a "master switch" level such that TNF family signaling can result  
in a large number of subsequent events best typified by TNF. TNF can initiate the  
15 general protective inflammatory response of an organism to foreign invasion which  
involves the altered display of adhesion molecules involved in cell trafficking,  
chemokine production to drive specific cells into specific compartments and the  
priming of various effector cells. As such, the regulation of these pathways has clinical  
potential.

20 The TNF receptor family is a collection of related proteins that generally consist  
of an extracellular domain, a transmembrane domain and an intracellular signaling  
domain. The extracellular domain is built from 2-6 copies of a tightly disulphide-  
bonded domain and is recognized on the basis of the unique arrangement of cysteine  
residues (Banner et al, 1993). Each receptor binds to a corresponding ligand(s)  
25 although one ligand may share several receptors. In some cases, it is clear that soluble  
forms of the receptors lacking the transmembrane region and/or intracellular domain  
exist naturally. In nature, truncated versions of these receptors may have direct  
biological regulatory roles. An example of this process is provided by the  
osteoprotegerin system. Osteoprotegerin is a secreted TNF family receptor that blocks  
30 signaling via the RANK-L (also called TRANCE) and/or TRAIL to receptors that  
trigger osteoclast activation. By blocking these receptors, most likely RANK receptor,  
bone resorption is hindered and bone mass increases (Bucay et al, 1998). Clearly,  
viruses have used this tactic to inhibit TNF activity in their host organisms (Smith et al,

1994). These receptors can signal a number of events including cell differentiation, cell death or cell survival signals. Cell death signaling often is triggered via relatively direct links to the cascade of caspase proteases in the case of the Fas and TNF receptors.

The TNF receptors are powerful tools to elucidate biological pathways since  
5 they are easily converted to immunoglobulin fusion proteins which have long serum  
halflives. Dimeric soluble receptor forms may be inhibitors of events mediated by  
either natural secreted or surface bound ligands. By binding to these ligands these  
fusion proteins prevent the ligand from interacting with cell associated receptors and  
inhibit the associated signal. These receptor-Ig fusion proteins are useful in an  
10 experimental sense, and have also been successfully used clinically, for example  
TNF-R-Ig has been used to treat inflammatory bowel disease, rheumatoid arthritis and  
the acute clinical syndrome accompanying OKT3 administration (Eason et al., 1996;  
Feldmann et al., 1997; van Dullemen et al., 1995). The manipulation of the many  
events mediated by signaling through the TNF family of receptors may have application  
15 in the treatment of immune based diseases as well as the wide range of human diseases  
that have pathological sequelae due to immune system involvement. For example, a  
soluble form of a recently described receptor, osteoprotegerin, has been shown to block  
the loss of bone mass (Simmonet et al, 1997). Thus, the events controlled by TNF  
family receptor signaling are not necessarily limited to immune system regulation.  
20 Antibodies to receptors can block ligand binding and thus also have clinical application.  
Such antibodies are often very long-lived and may have advantages over soluble  
receptor-Ig fusion proteins which have shorter half-lives in the blood.

While inhibition of the receptor- mediated pathway represents the most  
exploited therapeutic application of these receptors, originally it was the activation of  
25 the TNF receptors that showed clinical promise (Aggarwal and Natarajan, 1996).  
Activation of the TNF receptors can initiate cell death in the target cell and hence the  
application to tumors was and still is attractive (Eggermont et al., 1996). The receptor  
can be activated either by administration of the ligand, i.e. the natural pathway or by  
administration of antibodies that can crosslink the receptor. Antibodies may be  
30 advantageous for the treatment of, for example, cancers, since the antibodies can persist  
in the blood for long periods as opposed to ligands, which generally have short  
lifespans in the blood. Agonist antibodies are useful weapons in the treatment of cancer  
since receptors may be expressed more selectively in tumors or they may only signal

cell death or differentiation in tumors,. Likewise, many positive immunological events are mediated via the TNF family receptors, e.g. host inflammatory reactions, antibody production etc. and therefore agonistic antibodies could have beneficial effects in other, non-oncological applications.

5 Paradoxically, the inhibition of a pathway may also have clinical benefit in the treatment of tumors. For example the Fas ligand is expressed by some tumors and this expression can lead to the death of Fas positive lymphocytes, thus facilitating the ability of the tumor to evade the immune system. In this case, inhibition of the Fas system could then allow the immune system to react to the tumor in other ways now that access  
10 is possible (Green and Ware, 1997).

One member of this receptor family, the lymphotoxin-beta receptor (LT $\beta$ R) binds to surface lymphotoxin (LT) which is composed of a trimeric complex of lymphotoxin alpha and beta chains (Crowe et al, 1994). This receptor-ligand pair is involved in the development of the peripheral immune system and the regulation of  
15 events in the lymph nodes and spleen in the mature immune system (Ware et al, 1995; Mackay et al, 1997; Rennert et al, 1996; Rennert et al, 1997; Chaplin and Fu, 1998). A lymphotoxin- $\beta$  receptor- immunoglobulin fusion protein can be made between LT $\beta$ R and IgG (LT $\beta$ R-Ig) that blocks signaling between the surface LT ligand and the receptor with consequences on the functional state of follicular dendritic cells (Mackay and  
20 Browning 1998). This blocking can furthermore lead to diminished autoimmune disease in rodent models (Mackay et al, 1998, U.S.S.N. 08/505,606 filed July 21, 1995 and U.S.S.N. 60/029,060 filed October 26, 1996). A second member of this receptor family called HVEM for herpes virus entry mediator binds to a ligand called Light (Mauri et al, 1998) as well as the heteromeric LT ligand. The function of this receptor  
25 is currently unknown, but a HVEM-Ig fusion protein may be useful for the treatment of immunological disease and this construct has been shown to affect in vitro immune function assays (Harrop, J.A., et al, 1998).

Despite the clinical advances of members of the TNF Family as discussed above, there remains a need for a method of obtaining the desired yields of receptor Ig  
30 fusions suitable for use in a clinical setting. For example, the LT $\beta$ R-Ig protein can come in two forms when expressed in either monkey cos cells or in Chinese hamster ovary cells. One form binds ligand with high affinity whereas the other does not.

Therefore, there is a need for a method for producing higher yields of the form which binds with high affinity, while minimizing the presence of the lower affinity form.

#### SUMMARY OF THE INVENTION

The present invention relates to methods for the expression of high yields of the form of protein-Ig fusions having high affinity binding to its ligand, referred to herein as the "active" form, the form, by culturing hosts transformed with DNA encoding the desired fusions in a culture system at a low temperature thereby minimizing the amount of misfolded or misbridged protein forms. The invention in various embodiments relates to methods of expressing high yields in mammalian expression systems, by culturing transformed hosts at a temperature of about 27°C to about 35°C. Preferably, mammalian hosts will be cultured at a temperature of about 27° C to about 32°C.

In yet other embodiments the invention relates to methods for the expression of high yields of active fusion proteins by culturing transformed hosts in a yeast expression system at low temperatures. When the desired proteins are expressed in yeast, the preferred temperatures are from about 10°C to about 25°C, more preferably from about 15°C to about 20° C.

In certain methods of the claimed invention, the protein-Ig fusion comprises a member of the TNF receptor family such as a lymphotoxin- $\beta$  receptor or a fragment thereof. Alternatively, the claimed methods may encompass the expression of a desired fusion protein in any expression system at low temperatures, such as an insect or bacterial system.

In other embodiments, the claimed invention encompasses the active protein-Ig fusions that are obtained by the claimed methods, and pharmaceutical compositions comprising them. In yet other embodiments, the invention relates to methods of making pharmaceutical preparations comprising culturing a host transformed with DNA encoding a desired protein-Ig fusion in a culture system having a low temperature of about 27°C to about 35°C, preferably about 27°C to about 32°C, to express a high yield of active fusion proteins, recovering the active protein fusions from the culture system, and combining the active fusion proteins recovered with a pharmaceutically acceptable carrier. In preferred embodiments, the protein-Ig fusion comprises a lymphotoxin- $\beta$  or a fragment thereof, or HVEM, or a fragment thereof.



In still other embodiments, the claimed invention relates to pharmaceutical compositions obtained using the methods described.

The claimed invention in different embodiments relates to mammalian expression systems, as well as other expression systems, such as yeast, bacterial  
5 systems, or insect systems.

In certain embodiments, the invention relates to methods for high levels of expression of active fusion proteins in yeast, by culturing at low temperatures of about 10°C to about 25 °C, more preferably, about 15°C to about 20°C. Active fusions obtained by this method of expression in yeast, and pharmaceutical compositions  
10 comprising these active fusions are also encompassed. Methods of making pharmaceutical preparations are encompassed within the invention comprising active protein-Ig fusions comprising culturing a yeast cell transformed with DNA encoding a desired fusion at a low temperature, preferably about 10°C to about 25°C, more preferably about 15°C to about 20°C. In the most preferred embodiments of all the  
15 compositions and methods of the invention, the protein-Ig fusion comprises a lymphotoxin- $\beta$  receptor, HVEM, or a fragment thereof.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1:** Schematic of the receptor-immunoglobulin chimeric protein. The left panel shows a cartoon of a typical IgG molecule, the heavy chain variable domains are filled  
20 with black lines and the light chains are left white. The middle panel contains a schematic drawing of the LT $\beta$ R molecule including the intracellular (dark black lines) and extracellular (light black lines) domains. The right panel depicts a schematic drawing of the LT $\beta$ R-Ig fusion protein.

25 **Figure 2:** Conceptual schematic showing the likely defect in the dead LT $\beta$ R-Ig form, although the actual misfolded or misbridged amino acids have not been identified.

**Figure 3:** SDS-PAGE analysis of human LT $\beta$ R-Ig before and after treatment with PNGase F. Lanes 1 and 2 contain human LT $\beta$ R-Ig purified from CHO cell culture  
30 supernatant grown at 37 °C using Protein A affinity chromatography. Lane 3 shows the same preparation after treatment with PNGase F to remove all N-linked oligosaccharides. Lane 1 is run under nonreducing conditions, lanes 2 and 3 are run

under reducing conditions. The protein bands are visualized by staining the gel with Coomassie Brilliant Blue.

**Figure 4:** A nonreduced SDS polyacrylamide gel analysis of the protein flowing through an AGH1 affinity column lanes and the protein eluted with pH 3.5 phosphate buffer. The protein before affinity purification is shown in the lane on the right side of the gel. The protein bands are visualized by staining the gel with Coomassie Brilliant Blue.

**Figure 5A:** Ability of the flow through (lower filled circles) and eluted (upper filled squares) fractions from the AGH1 affinity column to bind to surface lymphotoxin. Mean fluorescence intensity values were derived from a FACS analysis as described.

**Figure 5B:** Examples of the FACS profiles are shown on the right where the LT $\beta$ R-Ig is compared to the binding of a control LFA-3-Ig protein.

**Figure 6:** Analytical HIC chromatography of human LT $\beta$ R-Ig using a POROS ether column and a decreasing gradient of ammonium sulfate. Peak 1 represents the lower, inactive form, peak 2 the larger, active form of human LT $\beta$ R-Ig. Fractions corresponding to peaks 1 and 2 respectively were pooled and analyzed on a 4 - 20% SDS-PAGE gel (inserted panel). The lane labeled "1" contains the "inactive" material from peak 1, lane 2 the "active" material from peak 2 of the HIC chromatogram. The starting material is shown in lane "L". The lane labeled "M" contains molecular weight markers.

**Figure 7:** Preparative HIC (hydrophobic interaction chromatography) chromatography of human LT $\beta$ R-Ig using a Pharmacia Source 15 PHE column. Protein A eluate containing human LT $\beta$ R-Ig is adjusted with 5 M NaCl to a final concentration of 1.5 M NaCl, 20 mM sodium phosphate, pH 7.0 and loaded onto the column. The column was washed with 5 volumes of 1.5 M NaCl, 20 mM sodium phosphate, pH 7.0 and eluted with 20 mM sodium phosphate, pH 7.0. The X-axis represents the time in minutes, the Y-axis shows the absorbance at 280 nm. Shown in the figure insert is the image of a

nonreducing 4-20% SDS-PAGE gel stained with Coomassie Brilliant Blue of the flow through (FT) and elution (E) pools. The migration positions of the “live” and “dead” forms are indicated with arrows.

5 **Figure 8:** SDS-PAGE/western blot analysis of human LT $\beta$ R-Ig secreted from CHO cells grown at different temperatures. The CHO cell supernatants grown at the indicated culture temperatures containing human LT $\beta$ R-Ig were analyzed in duplicate by nonreducing SDS-PAGE electrophoresis using 4-20% gradient gels followed by western blotting.

10

**Figure 9:** Effects of culture temperature on the percentage of dead material in the total amount of human LT $\beta$ R-Ig secreted from mammalian cells. Duplicate flasks containing CHO cells secreting recombinant human LT $\beta$ R-Ig were cultured at the indicated temperatures and the secreted human LT $\beta$ R-Ig was purified by Protein A  
15 affinity chromatography. The percentage of the “inactive” form of human LT $\beta$ R-Ig was assessed in duplicate using analytical HIC chromatography. The X-axis represents the culture temperature, the Y-axis shows the amount of “inactive” material expressed as a percentage of the total amount of human LT $\beta$ R-Ig secreted by the cells.

20 **Figure 10.** Nonreducing SDS-PAGE analysis of HVEM-Ig prepared at 28, 32 and 37°C: Protein A purified preparations of HVEM-Ig derived from cells cultured at 28, 32, and 37°C were mixed with nonreducing SDS-PAGE sample buffer and electrophoresed on precast 4-20% SDS-PAGE gels. The protein bands were visualized with coomassie blue. The band marked with an arrow represents unaggregated HVEM-Ig. The higher molecular weight bands visible on the gel correspond to aggregated  
25 forms.

**Figure 11:** FACS analysis of the binding of HVEM-Ig generated at 37° vs 32° C to surface Light and/or LT $\alpha\beta$ . A). Binding of HVEM-Ig as a function concentration to  
30 293 cells transfected with human LIGHT showing that material generated at 32 C binds better than 37 material. B). An example of the FACS profiles observed of HVEM-Ig binding at a concentration of 2 ug/ml to LIGHT transfected 293 cells. C).



A further example of the improved binding of 32 C generated HVEM-Ig to the surface of the II-23 T cell hybridoma line which displays both LIGHT and surface lymphotoxin- $\alpha\beta$  (LT $\alpha\beta$ ) complex.

5 **Figure 12:** A BIAcore analysis of the binding of LIGHT ligand at A) 37C; B) 32C; C) 28C or lymphotoxin- $\alpha$  (LT $\alpha$ ) ligand at D) 37C; E) 32C; F) 28C to BIA core chips immobilized HVEM-Ig generated at three different temperatures. Each curve shows a binding event at one concentration of ligand and the following concentrations were employed: 30, 15, 7.5, 3.75, 1.87, 0.93, 0.47, 0.23, 0.11 and 0.0 ug/ml. Each chip was  
10 loaded to the same RU level indicating that equal amounts of receptor-Ig were bound.

#### DETAILED DESCRIPTION

Reference will now be made in detail to the claimed invention. This invention concerns the ability to produce high levels of functional or active forms of immunoglobulin fusion proteins of receptors in the TNF family. The success of clinical  
15 interventions with receptor-Ig fusion proteins requires a long term presence and the ability to treat chronically or a minimum during disease flares. Ideally, preparations of such fusion proteins for human use will not have any aggregated, inactive or misfolded forms as their presence will reduce the potency of the drug and the altered structures could elicit antibody responses that may facilitate clearing of the drug thereby reducing  
20 its potency. Moreover, anti-receptor antibodies can directly cross link natural receptor on the cell surfaces thereby activating them, i.e. agonistic antibodies such as those described in Browning et al 1996, JEM. Agonistic antibodies activate the system and thus further receptor-Ig treatments may be less effective or even detrimental. By "immunoglobulin fusion proteins" we refer to any fusion of any functional portions of  
25 the extracellular domain of a polypeptide with any portion of the immunoglobulin constant regions, e.g. the CH1, CH2 or CH3 domains or combinations thereof. Preferably the polypeptide is a member of the TNF family of receptors. The portions of the Ig molecule may derive from any of the various immunoglobulin isotypes, including, for example, IgG1, IgG2, IgM, IgA etc. By "TNF family of receptors" we  
30 refer to any receptor, whether naturally membrane bound or secreted (as in the case of osteoprotegerin), which has the canonical TNF family cysteine bridging patterns or any receptor which binds to a defined member of the TNF family of ligands (e.g. Banner et al, 1993). The claimed invention in other embodiments relates to TNF family receptor-

Ig fusions obtained by the methods discussed herein, as well as to pharmaceutical preparations comprising them.

LT $\beta$ R-Ig protein is expressed in two forms in monkey cos cells or Chinese hamster ovary cells. One form binds ligand with high affinity, the "active" form  
5 whereas the other, the "inactive" form does not. This mixture of live and dead forms has not been described previously for any of the TNF receptor-Ig fusion proteins, however, the nature of the inactive form is not clear. The two forms were discovered by the presence of two bands in an SDS-PAGE analysis. The expressed material contains considerable glycosylation heterogeneity; however, this heterogeneity most  
10 likely does not result in the functional problems described here. For example, when the receptor is expressed as a soluble monomeric form lacking the transmembrane domain and the immunoglobulin Fc region, non-, mono- and di-N-linked glycosylated forms are observed. Both single and double glycosylated forms can be immunoprecipitated by BDA8, an antibody that recognizes only functional forms. Moreover, the affinity-  
15 purified forms have similar glycosylation heterogeneity. More likely, we speculate that the expression of a non-membrane anchored form leads to some aberrant disulfide linking resulting in inappropriate crosslinking between the two arms of the receptor-Ig dimer.

The TNF family of receptors generally 3-4 repeated domains in the extracellular  
20 ligand binding portion with about 3 disulfide bridges per domain. It is conceivable that inappropriate folding would lead to either an incorrect pattern of disulphide bonds or the lack of some formation of disulphide bonds (illustrated schematically in figure 2). In the case of a receptor-Ig fusion protein, it appears that the early folding of the Fc domain enables its subsequent dimerization which brings the two LTBR chains, i.e. the  
25 two receptor arms, into close proximity. If the receptor domains have not yet completed their folding, then there is the potential for free sulfhydryls to pair between the arms, i.e. interarm bridging. Such incorrect folding may occur, or disulfide scrambling may result between free sulfhydryls juxtaposed next to already formed disulfide linkages in both cases leading to folding errors. It is also possible that  
30 incorrect folding occurs within one arm i.e. intra-arm folding errors, although such errors may not result in a radically different shape of the final molecule. In this case, active and inactive forms may not be readily resolvable using conventional sizing methods.

Lastly, in the TNFR55 receptor, the fourth domain, i.e. the domain closest to the transmembrane region has been demonstrated to be critical for ligand binding when the receptor was expressed as an Ig fusion protein (Marsters et al, 1992). This domain may be critical for many of TNF receptors. Another study on TNFR55 showed that it was  
5 critical only in the context of the Ig fusion protein, and that the membrane form lacking the fourth domain was fully active in binding TNF ligand (Corcoran et al, 1994). However, more recently, crystallographic analyses have pointed to possible critical functions associated with the fourth domain (Naismith et al, 1996). The fourth domain is relatively conserved between species yet lacks direct contacts with the ligand (Banner  
10 et al, 1993). It is possible that interarm bridging in this region between the two fourth domains which lie next to the hinge and CH2+CH3 Fc domains would not appreciably alter the global shape of the molecule and hence may be invisible in size-based separation methods. Nonetheless, this molecule would exhibit impaired ligand binding. Receptors having only 3 domains could behave in a similar fashion.

15 Reducing the the temperature during cell culture resulted in significantly less of the misfolded smaller form (i.e. the inactive form) being secreted. This improvement is presumably due to a reduced folding rate of the polypeptide which would allow for more time to fold the individual domains of the LT $\beta$ R portion prior to assembling the receptor-Ig fusion protein into the expected dimer form. The absolute temperature  
20 required to slow down the folding process is host dependent. For mammalian cells (i.e. CHO), the claimed method preferably occurs at temperatures of about 27°C to about 35 °C, more preferably, the temperature is about 27°C to about 32°C. Claimed methods also can be used in yeast culture systems. Yeast culture needs to be grown at temperatures of about 10°C to about 25°C, preferably from about 15°C to about 20°C  
25 to achieve significant benefit.

Exploitation of the claimed invention allows the correct folding of active protein Ig fusions. It may be desirable, in some circumstances, to allow cell growth at higher temperatures, for example, about 37°C to about 43°C, during which only a very low level of expression of the cloned gene will occur. After the desired growth period, the  
30 fusions can be expressed at the low temperatures, to produce an increased yield of active fusions. The low temperatures in mammalian systems, as discussed above, are preferably about 27°C to about 35°C, more preferably about

27°C to about 32°C.

Thus, the claimed methods, by lowering the temperature at which the protein-Ig fusions are expressed, allow one skilled in the art to regulate the folding of both the protein and the Ig portions of the desired protein.

5        Additionally, using the claimed method including affinity and/or the conventional chromatography techniques, one can now purify the active fractions sufficiently to use the chimeric proteins to block immunological function in various clinical settings. In addition, using the claimed methods having low temperature (i.e.  $\leq 32^\circ\text{C}$  for CHO and  $\leq 25^\circ$  for yeast) cell culture conditions, it is now possible to prepare  
10        culture supernatant that is highly enriched in the larger, active form of human LT $\beta$ R-Ig. Moreover, it is possible that other members of this family of receptors suffer from similar problems. For example, we see two similar bands on non-reducing SDS PAGE for the TNFR55-Ig (also called the p55 or p60 TNFR). Similarly, the properties of another TNF family receptor called HVEM are improved by secretion at lower  
15        temperatures. This receptor may form an example of an intra-arm folding error as there are no obvious size differences in the materials made at the various temperatures. Nonetheless, regardless of the mechanism, the claimed methods having results in a higher percentage of lowered secretion temperatures more active fusion proteins in preparations of the se and other member of the TNF family.

20

### Examples

#### Example 1. mAb that specifically recognize the live form of human LT $\beta$ R-Ig

The LT $\beta$ R-Ig protein (Figure 1) when secreted from either COS or CHO cells transfected with a plasmid can be purified using standard protein A based affinity  
25        chromatographic methods. The purified protein consists of two closely spaced bands at about 100 kDa on a nonreducing SDS acrylamide gel (Figure 3). The two bands differ by about 5 kDa in apparent size. When the protein is reduced, essentially two bands at about 50 kDa are resolved resulting from heterogeneous glycosylation (Figure 3). The two bands observed under nonreducing conditions, however, do not result directly from  
30        the glycosylation differences that give rise to the pair of reduced bands. Using a panel of monoclonal antibodies to the human LT $\beta$ R, we showed that antibodies from group I, i.e. AGH1 and BDA8 recognize only the large MW form of the receptor (Table I; all data except the selectivity for the upper and lower bands was taken from Browning et

al, 1996). Antibodies from this group bind directly to the ligand binding region as evidenced by the observation that an Fab fragment of BDA8 can still block. Group II mAbs can also block ligand binding, however, in biological assays, these mAbs show mixed agonist and antagonist behavior. When one makes an affinity column from these mAbs (AGH1 was used in these experiments) and applies the mixture of large and small forms of the LT $\beta$ R-Ig, the smaller form of the receptor flows through and the larger form sticks to the column matrix. Low pH elution yields a pure preparation of the large form (Figure 4). The two fractions were assayed for their ability to bind to the surface phorbol ester activated II-23 T cell hybridoma cells, i.e. cells expressing surface lymphotoxin complex (as described in Browning et al, 1995), and only the fraction that bound to the mAb was able to bind to surface lymphotoxin. The flow through fraction, i.e. the lower MW band was completely inactive (Figure 5). Specifically, supernatants from CHO cells stably transfected with the LT $\beta$ R-Ig construct were passed over a protein A column to isolate the protein. Pure protein was eluted with 25 mM sodium phosphate buffer at pH 2.8 and the protein containing fractions were neutralized with 1/10 volume of 0.5 M sodium phosphate, pH 8.6. Immunoprecipitations were carried out in a volume of 0.25 ml with 3 ug of LT $\beta$ R-Ig and 4 ug of anti-LT $\beta$ R mAb followed by capture of the mAb with KappaLock sepharose beads which recognize only the kappa chain on the mouse mAb and not the human Fc domain. The beads were removed by centrifugation and the supernatant was cleared of remaining immunoglobulin with protein A sepharose. Beads were treated with SDS PAGE sample buffer (no reducing agent) and the buffer was loaded onto SDS-PAGE gels. Gels were run and transferred onto Hybond and western blotted with anti-human IgG Fc fragment conjugated to horse radish peroxidase (LT $\beta$ R mAb followed by anti-mouse IgG-HRP and chemiluminescence detection of HRP (Amersham).

To exploit the ability of AGH1 that exclusively recognizes the active form of LT $\beta$ R:Ig, an AGH1 affinity column was prepared using CNBr-activated sepharose (Pharmacia, Piscataway, NJ) according to manufacturers protocol. The column was extensively washed with PBS and the protein A purified LT $\beta$ R-Ig was applied and the flow through collected. The column was washed with PBS and then eluted with 25 mM sodium phosphate, pH 2. Fractions containing eluant were immediately neutralized as described above. Protein concentrations were determined by absorbance



at 280 nm assuming that a 1 OD solution equals 1 mg/ml. The flow-through and elution pools containing LT $\beta$ R-Ig were tested for binding by FACS analysis as described (Browning et al, 1995). The flow-through fraction showed no FACS staining to cells expressing surface LT whereas the elution pool retained full binding activity.

5

**Example 2. Conventional chromatographic separation of live and dead components of human LT $\beta$ R-Ig.**

Potential structural differences between the large and small MW components identified above are exploited in the design of separation methods using conventional chromatography steps. As an example, the protein can be sized by gel filtration in PBS to obtain partial separation of the larger and smaller forms. These preparations can then again be applied to the same column to obtain preparations of the larger and smaller forms of human LT $\beta$ R-Ig that are greater than 90% enriched in the respective components. Alternatively, hydrophobic interaction chromatography (HIC) can be employed to achieve the same result. The protein mixture is diluted with ammonium sulfate, loaded on the HIC column and the large and small components are differentially eluted with a decreasing salt gradient. Under these conditions, baseline separation of the two human LT $\beta$ R-Ig components is obtained (Figure 6). These methods as well as the immunoaffinity method described above are useful to prepare mg amounts of the large and small preparations of human LT $\beta$ R-Ig but leave much to be desired for the preparation of large amounts of these components for pharmaceutical use. Applicants have invented a new method by adapting the HIC method to resins that can be obtained in bulk and have identified chromatography conditions that permit the small form of human LT $\beta$ R-Ig material to flow through the column while the large component is retained and can be selectively eluted (Figure 6). The eluted material can be subjected to a finishing step such as size exclusion or ion exchange chromatography to remove aggregated material and other impurities and, which, after formulation into a suitable physiological buffer can be used for in vivo work. The first example below (A) describes the specific conditions that were used to analytically assess the amount of inactive material in a preparation of LT $\beta$ R-Ig. The second example (B) describes the preparative purification process that results in a preparation of LT $\beta$ R-Ig highly enriched in the active component.

***A). Analytical hydrophobic interaction chromatography (HIC) can be used as a quantitative assay to assess the amounts of inactive LT $\beta$ R-Ig***

Baseline resolution of the smaller, inactive and the larger, active components of recombinant human LT $\beta$ R-Ig was achieved on a Perseptive Biosystems Poros ether/m column (4.6x100 mm, catalogue No. P091M526) equilibrated in 1.5 M ammonium sulfate and subsequent elution in a decreasing gradient of ammonium sulfate. The LT $\beta$ R-Ig preparations were diluted to a concentration of 0.1 mg/ml and brought to a final buffer composition of 1.5 M ammonium sulfate, 20 mM sodium phosphate, pH 9 (buffer A). A portion (1 ml containing 100  $\mu$ g of protein) was loaded onto the Poros ether/m column. The column was washed with 8.3 ml of buffer A. The active and inactive components were differentially eluted with a linear gradient (total gradient volume of 16.6 ml) from 100% buffer A to 100% buffer B (20 mM sodium phosphate, pH 9) followed by a 16.6 ml wash with buffer B. The column effluent was monitored for absorbance at 214 nm. The whole procedure was carried out at ambient temperature using a column flow rate of 1 ml/min. The elution profile of a representative analytical HIC chromatogram is shown in Figure 5. Peak 1 contains the inactive fraction and peak 2 the active fraction of LT $\beta$ R-Ig. In order to quantify the relative contribution of the two forms, the peak areas were integrated using the Perseptive instruments Vison integration software.

***B). Preparative purification of human recombinant LT $\beta$ R-Ig.***

***Clarification and concentration of conditioned media:*** The cell debris was removed from 10L of conditioned media harvested from CHO cells secreting recombinant LT $\beta$ R-Ig using dead end filtration through a 5  $\mu$  polypropylene 5 sqft. Calyx filter capsule (Microseparations Inc, Westborough, MA) followed by a 0.2  $\mu$  Opticap 4 inch filter cartridge (Millipore Corp., Bedford, MA). The clarified media was concentrated by ultra filtration to approximately 1 L using three S1Y30 Spiral Ultrafiltration cartridges (Amicon, Beverly, MA) connected in series.

***Protein A affinity Chromatography:*** The concentrated conditioned medium was passed by gravity through a 10ml Protein A sepharose fast flow (Pharmacia) column at 4°C. The column was washed with 50 ml of PBS, 50ml of PBS containing 0.5 M NaCl, and 50ml of PBS. To remove contaminating bovine IgG, the column was washed with 50ml of 25 mM sodium phosphate, pH 5.5. The bound LT $\beta$ R-Ig was eluted by gravity

with 25 mM sodium phosphate, 100 mM NaCl, pH 2.8 in 3ml fractions and immediately neutralized with 0.3ml of 0.5 M sodium phosphate, pH 8.6. Fractions containing protein were identified by absorption spectroscopy, pooled and stored at -70°C.

5            *Hydrophobic Interaction Chromatography:* The protein A elution pool (40ml at a concentration of 2.5 mg/ml) was diluted with 40 ml of 3 M sodium chloride, 40 mM sodium phosphate pH 7 and 20 ml of 1.5 M sodium chloride, 20 mM sodium phosphate pH 7 (all solution were at ambient temperature). The diluted pool was loaded onto a 10x100 mm (7.8 ml) Source PH15 (Pharmacia, Piscataway NJ) at a flow  
10 rate of 2 ml/min. The column was washed with 79 ml of 1.5 M sodium chloride, 20 mM sodium phosphate pH 7 at a flow rate of 20 ml/min. The bound protein was eluted with 20 mM sodium phosphate pH 7 at a flow rate of 2 ml/min. The absorbance of the effluent was monitored at 280 nm and 9 ml fractions were collected. Elution fractions containing protein were identified by UV absorption spectroscopy, pooled and stored at  
15 -70°C. Figure 7 represents a typical HIC elution profile. Under these conditions, the inactive material flows through the column and the active material is bound to the resin. The figure 7 insert contains a scan of the coomassie blue stained NR SDS-PAGE analysis of the follow-through and elution pools, respectively.

*Size Exclusion Chromatography:* Approximately 100 ml (1.3 mg/ml) of the  
20 HIC elution pool containing the active components of LTβR-Ig were concentrated by ultrafiltration to 9 ml using a centriprep30 concentrator (Amicon, Beverly, MA). The concentrate (10.3 mg/ml) was loaded onto a 1.6x100 cm Superose-6 prep grade (Pharmacia, Uppsala, Sweden) column equilibrated in PBS at a flow rate of 1ml/min. The effluent was collected in 3 ml fractions. Fractions containing protein were  
25 identified by UV absorption spectroscopy. Selected fractions were analyzed for aggregate content at a 3 µg/lane load using NR SDS-PAGE gel electrophoresis. Fractions with minimal visible aggregate were pooled and stored frozen at -70°C.

          In this fashion, LTβR-Ig can be prepared that contains minimal amounts of the inactive LTβR-Ig component that is present in the crude culture media.

30

**Example 3. Low temperature fermentation conditions enrich for the large, active component of human LTβR-Ig during the cell culture stage.**

Under conventional mammalian cell culture conditions, human LTβR-Ig is

secreted as a mixture of approximately 50% small and 50% large components. Using baculovirus infected insect cells to express the same protein results in drastically reduced levels of the small form. As insect cells are cultured at 28°C, we explored if human LTβR-Ig secreted from mammalian cells grown at low temperature would have an altered ratio of large and small forms. Shown in Figure 8 are the supernatants from CHO cells secreting human LTβR-Ig cultured in T-flasks at 28, 30, 33, 35, and 37°C analyzed by western blot. The large and small forms (indicated by arrows) are present in the cultures grown at 33, 35, and 37°C. Very little evidence of the small form can be seen in the lanes containing culture supernatant from cells grown at 30 and 28°C. Thus, lowering the temperature during cell culture dramatically reduces the amount of the small, inactive form of human LTβR-Ig. To quantify the relation ship between cell culture temperature and the extent of the enrichment for the larger, active form of human LTβR-Ig, duplicate culture flasks were set up and grown at temperatures ranging from 28 - 37°C in one degree intervals. The protein A affinity purified human LTβR-Ig samples were analyzed by analytical HIC chromatography to quantify the ratio of the small and large components of human LTβR-Ig present in the preparations derived from cells grown at the different temperatures. As shown graphically in Figure 9, the amount of the lower band rapidly decreases approximately 5 fold when the culture temperature is lowered from 37 to 32 °C. Lowering the culture temperature to 28 °C reduces the amount of the lower form but in a much less dramatic fashion. These results show that reducing the culture temperature by only a few degrees from 37 °C dramatically decreases the amount of the smaller mw component, thus increasing the yield of the larger active component of human LTβR-Ig. Based on these data, culture temperatures of 32 and 28°C were selected to test if these observations could be duplicated on a large scale under conditions that would be suitable for manufacturing using CHO cells secreting recombinant human LTβR-Ig that had been adapted to growth in suspension. For these experiments, the cells were grown to densities approaching  $2 \times 10^6$  cells/ml at 37 °C the culture was diluted with approximately 4 volumes of growth media and incubated at 32 °C until the cell viability dropped below 80%. Lowering the temperature to 28°C during the production phase also results in significantly lower levels of the inactive component in the final harvest. It was interesting to note that while the cell number did not increase very much during the production phase at 28 or 32 °C,

a several fold increase in product titer over culture grown exclusively at 37 °C was obtained in the harvested conditioned media. The specific conditions that were used in the 32 and 28 °C process are described below.

Initial data suggests that lowering the culture temperature results in similar  
5 benefits in other host systems such as yeast. It is interesting that in yeast, the beneficial effects of low temperature production are observed at much lower temperatures than in mammalian cells. Yeast cultured at 30°C produce predominantly the inactive form, cultures grown at 25 °C contain about an equal mixture of the inactive and active forms and cultures fermented at 16 °C produce predominately the active form of human  
10 LTβR-Ig. These observations suggest that low temperature fermentation will result in significantly higher yields of the active component of human LTβR-Ig in any secretory host system. One skilled in the art can easily determine the optimal production temperatures for each system.

Here we provide a detailed example of how this process was applied to the  
15 production of LTβR-Ig. Two cell culture methods were developed that take advantage of the fact that reducing the cell culture temperature significantly reduces the amount of the inactive components present in LTβR-Ig secreted from host cells. An additional, unexpected benefit of low temperature fermentation is a several fold improvement in titer when compared to traditional fermentation runs carried out at 36-37°C. Table II  
20 summarizes the comparative yields and the relative amounts of inactive LTβR-Ig components obtained with two different cell lines transfected with different LTβR-Ig constructs which varied in the extent of glycosylation (not germane to the thrust of this example).

25        *32 °C Cell Culture Process:* CHO cells secreting human LTβR-Ig that had been adapted to growth in suspension were grown in DME/HAM's F-12 growth media (see Table III below) supplemented with 10% FBS, 140 mg/L streptomycin, and 50 mg/L gentamycin. For scale-up, two 750ml-spinner flasks were inoculated at approximately  $2 \times 10^5$  cells/ml in growth media. The cultures were grown at 37°C in a 5% CO<sub>2</sub>  
30 atmosphere to a density of approximately  $3 \times 10^6$  cells/ml. The cell suspensions from both spinner cultures were combined to inoculate the scale-up bioreactor containing approximately 10L of growth media. The culture was oxygenated at 11% O<sub>2</sub> and grown



for three days at 37°C to a density of approximately  $2 \times 10^6$  cells/ml. This culture was used to inoculate the production bioreactor containing 33L of growth medium at a density of  $6.4 \times 10^5$  cells/ml. The production bioreactor was then cultured for 8 days at the beneficial temperature of 32°C with the oxygen sparge rate set at 11% O<sub>2</sub>. The cell density on the harvest day (day 8) was approximately  $2 \times 10^6$  cells/ml with a viability of approximately 60%. Under these conditions, a titer of 12 mg/L LTβR-Ig was achieved which was two-fold higher than when the same cells were cultured at the traditional temperature of 37°C. The relative amount of the inactive component in the LTβR-Ig preparation was 17% which represented a more than 60% decrease when compared to product obtained from a 37°C culture.

*28 °C Cell Culture Process:* CHO cells secreting human LTβR-Ig that had been adapted to growth in suspension were grown in DME/HAM's F-12 growth media (see table III below) supplemented with 10% FBS, 140 mg/L streptomycin, and 50 mg/L gentamycin. For scale-up, two 800 ml-spinner flasks were inoculated at approximately  $2 \times 10^5$  cells/ml in growth media. The cultures were grown at 37°C in a 5% CO<sub>2</sub> to a density of approximately  $3.5 \times 10^6$  cells/ml. The cell suspensions from both spinner cultures were combined to inoculate the scale-up bioreactor containing approximately 10 L of growth media. The culture was oxygenated at 11% O<sub>2</sub> and grown for two days at 37°C to a density of approximately  $1.7 \times 10^6$  cells/ml. This culture was used to inoculate two 40L and one 10 L production bioreactor at starting cell densities of  $2.5 - 3 \times 10^5$  cells/ml using a split ratio of 1:9. The production bioreactors were cultured at 37°C and oxygenated at 11% O<sub>2</sub> until a cell density of approximately  $2 \times 10^6$  cells/ml was reached (two days). At the end of day two, the bioreactor temperature was lowered to 28°C and the bioreactors were cultured for an additional 5 days. On day 7, at cell densities of approximately  $3 \times 10^6$  cells/ml and cell viability of >75%, the bioreactors were harvested and the conditioned media was processed as described above. Under these conditions, a final titer of approximately 20 mg/L LTβR-Ig was achieved which represents a 3.3 fold increase over the titer that was obtained when the same cells are cultured at 37°C. The relative proportion of the inactive component was 10% which represents a 80% decrease over the material prepared at 37°C.

#### **Example 4: Alterations in the Fc Domain to Minimize Dead Forms During Production**

Based on our hypothetical explanation of why dead molecules result in these preparations, one would predict that slowing the time before Fc domains would dimerize would increase the fraction of correctly folded receptor domains. We explored several methods to achieve this result. It is possible that different Ig Fc domains would fold at different rates, yet exchange of the IgG1 domain for an IgG4 domain did not change the live dead ratio. Secondly, the cysteine residues in hinge region that crosslink the two peptide chains were removed from the IgG1 Fc domain by mutagenesis. The Fc domains can dimerize well in the absence of hinge disulfide formation but the rate may be slower in its absence. Replacement of the two cysteine residues by alanine resulted in a decreased amount of dead form as quantitated by SDS-PAGE and HIC chromatography such that where wild type LT $\beta$ R-Ig would contain 50 and 5% dead forms at 37 and 28 °C, the deletion of the cysteines from the IgG1 hinge lead to 20 and 5 % dead form when produced at these respective temperatures. Therefore, hinge modification by replacement of both cys residues can improve the quality of a preparation and, moreover, it is possible that replacement of only one cys residue could have a beneficial effect. Such genetic modifications could reduce the percentage of dead form with recourse to low temperature production methods.

#### **Example 5: Deletion of Cystine Bridges to Correct Folding Problems**

Typically, it is very difficult to define the folding pathways utilized by a protein to get to the final correct form. Nonetheless, some disulfide bridges in the TNF receptor family are unusual and may not be needed for the final folded state. These bridges are good candidates for mutagenesis. One such bridge in the third domain of LT $\beta$ R-Ig was removed by conventional site directed mutagenesis of cysteines 101 and 108 to alanines (using the numbering from the sequence defined in Ware et al, 1995) led to an improved ratio of dead/live material as evidenced by SDS-PAGE. With wild type LT $\beta$ R-Ig typically shows the presence of 50 and 5% dead form when produced at 37 and 28 °C respectively. The mutant form with the one cystein disulfide bridge deleted had 20 and 5% dead form when produced at these temperatures.

#### **Example 6: Use of lower temperatures to improve the quality of a preparation of HVEM-Ig**

Herpes virus entry mediator (HVEM) is a TNF family receptor related to the

LT $\beta$ R and binds tightly to the ligand LIGHT tightly and weakly to the ligand lymphotoxin-a (LTa) (Mauri et al, 1998). Human HVEM was prepared as a Ig fusion protein by PCR amplification of the extracellular domain and fused to the human IgG1 CH2 and CH3 region as described for LT $\beta$ R-Ig (Crowe et al, 1994). The construct was  
5 inserted into a vector called CH269 (Chicheportiche et al, 1997) for transient expression in the human embryonic kidney cell line 293 with high copy vector expression using the EBNA system (293-E cells). Supernatants were collected and HVEM-Ig purified using ProteinA affinity chromatography and low pH elution. Recombinant LT $\alpha$  was prepared from insect cells as described (Browning et al, 1996a).  
10 Recombinant soluble human LIGHT was prepared by PCR amplification of the entire cDNA using RNA from activated II23 cells yielding the coding region of the sequence described by Mauri et al, 1998. The receptor binding domain of LIGHT was amplified by PCR and fused onto the alpha mating factor leader sequence and expressed essentially as described for other related proteins (Browning et al, 1996). A FLAG tag  
15 and (G<sub>4</sub>S)<sub>3</sub> spacer amino acid sequences were inserted between the leader and the receptor binding domain such that the secreted LIGHT would possess a N-terminal FLAG sequence. The construct encoded the following molecule:  
"MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVL PFSN  
STNGLLFINTTIAASIAAKEEGVSLEKR. . EADYKDDDDNGGGSGGGSGGGSKELNPA  
20 AHLTGANSSLTGSGGPLLWETQLGLAFLRGLSYHDGALVVTKAGYYYIYSKVQLGGVG  
CPLGLASTITHGLYKRTPRYPEELELLVSQQSPCGRATSSSRVWWDSSFLGGVVHLEA  
GEEVVVRVLDERLVRLRDGTRSYFGAFMV"  
where the two dots indicates the expected N-terminus of the mature protein which could be further processed by removal of the next two amino acids (EA). The protein  
25 was purified from the supernatant by affinity chromatography over an anti-FLAG mAb column and elution with either low pH or calcium chelation. Full length LIGHT was also inserted into a vector CH269 for expression on the surface of 293-E cells as described (Chicheportiche et al, 1997). FACS binding methods for the detection of receptor-Ig to cell surfaces and BIAcore methods for measuring the binding of soluble  
30 ligands to immobilized receptor-Ig have been described (Mackay et al, 1997). The BIAcore technology yields real time measurements of protein bound to the chips (i.e. the receptor).

CHO cells expressing HVEM-Ig were grown to confluency at 37 C in roller bottles using growth media supplemented with 10% FBS. When the cells reached confluence, the spent media was exchanged with fresh growth media and the cultures were incubated at 37, 32 and 28 C. The 28 and 32 C cultures were harvested once a week, the 37 C culture every 4 days. The secreted HVEM-Ig was purified using Protein A affinity chromatography as described. The purified preparations were stored at -70 C until analyses. When HVEM-Ig was produced at 28, 32 and 37° C and purified, all the preparations behaved similarly on SDS-PAGE analysis (figure 10) suggesting that large alterations in the protein did not occur. Therefore, if aberrant folding/disulfide bridging occurred, it was either intra-arm or occurred close to the hinge region of the Fc domain, i.e. inter-arm bridging and hence did not appreciably affect the overall shape of the molecule in SDS-PAGE. The ability of the receptor-Ig to bind to LIGHT expressed on 293-E cells or LIGHT on activated II23 cells was assessed in FACS binding assays (figure 11). On both cell types, the ability of HVEM-Ig to bind cell surface ligand was improved roughly 2-3 fold upon expression at 32 C. Using BIAcore technology, it was observed that when BIAcore chips were loaded with HVEM-Ig to similar levels (RU values reflect amount of protein on the chip), HVEM-Ig produced at lower temperatures bound more ligand than proteins produced at the higher temperatures (figure 12). This result was obtained whether LIGHT or LT $\alpha$  was the ligand. The BIAcore binding curves show the realtime on and off binding events and it can be seen that the binding events were similar regardless of the production temperature. Therefore, a portion of the preparation is effectively dead and this proportion is minimized by lower production temperatures. We speculate that the lower temperature has corrected an aberrant folding problem and improved the percentage of live molecules even though we cannot directly observe the fraction of dead molecules. Affinity chromatographic techniques as outlined above could serve to resolve the live/dead forms following optimization of the preparation by lowered growth temperatures and or mutagenesis of various cysteines either in the hinge or in the receptor itself to prevent incorrect folding.

#### **Example 7: Generic Schemes to Minimize Dead Forms of Other TNF-family Receptor-Ig Fusion Proteins**

Most receptors of the TNF family have been prepared as fusion protein constructs with immunoglobulin-Fc domains:

Reference

	p55 TNF-R	(Loestcher et al, 1991, Marsters et al, 1992; Ashkenazi et al, 1991)
	p75 TNF-R	(Mohler et al, 1993)
5	LT $\beta$ -R	(Crowe et al, 1994)
	Fas	(Suda et al, 1993)
	CD27	(Goodwin et al, 1993)
	CD30	(Smith et al, 1993)
	CD40	(Fanslow et al, 1992)
10	Ox40	(Baum et al, 1994)
	4-1BB	(Alderson et al, 1994)
	HVEM	(Mauri et al, 1998)

In several cases, most notably, Fas-Ig and CD40-Ig e.g. Fanslow et al, 1992, the  
15 chimeras are poorly active relative to the soluble Fc forms of the two TNF receptors. It  
is possible that some of these preparations are mixtures of live and dead forms in  
varying ratios. A dead form refers simply to a molecule that binds with a affinity  
substantially (10-1000 fold) lower than the live form, i.e. it may not be completely lack  
binding activity, but instead has a reduced affinity for ligand relative to the high affinity  
20 form found on cells naturally. Abberant inter-receptor arm or intra-receptor arm  
disulphide linkages may occur leading to a less active protein.

With any of these receptors or other as yet undefined receptors, a panel of anti-  
receptor mAbs would be prepared by conventional technologies. Those antibodies able  
to block the binding of the ligand to the receptor preferably as assessed using a ligand  
25 binding assay to the native receptor on a cell surface (although other methods using  
recombinant receptor forms may suffice) would be used to form affinity columns. The  
preparation of the mixture of live and dead receptor-Fc forms would be passed over the  
column and the flow through collected. The material that bound to the column would  
be eluted with a low pH buffer (typically pH 2.5 to 4.0) immediately neutralized. The  
30 two fractions would be bound to either cells in a FACS binding assay (or any other  
standard binding format) or ligand at varying protein concentrations. Some of these  
mAbs will selectively bind to the live form and a difference between the concentration  
needed to get 50% binding of the flow through vs eluate will be seen. This result marks



that mAb as a demarcating mAb. The ratio of the protein in the eluate to the flow through will indicate the percent live form in the preparation.

These mAbs thus identified can be used to affinity purify the live form. Moreover, their use in various immunoassay formats can be used to optimize for  
5 expression of the correct form of the desired receptor-Fc form. The assay can further be used in conjunction with other conventional purification methods to find methods that would purify the active form of the receptor without resort to affinity techniques. Using these Abs to delineate live and dead forms, the culture temperature could be optimized and chromatographic methods developed to enrich for the live form. Alternatively, HIC  
10 column methods could be exploited to separate live and dead forms and using this method, culture conditions could be optimized. Likewise, these assays would form the basis for cysteine mutagenesis of the receptor portion to define problem disulfide bonds which upon removal would yield functionally active material.

As many of these receptors will have application as therapeutic agents in human  
15 disease and one will want to put only properly folded forms into a patient, these methods for both defining the preparation and removing poor binding forms will have utility.

It will be apparent to those skilled in the art that various modifications and variations can be made in the methods of the present invention without departing from  
20 the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided that they come within the scope of the appended claims and their equivalents.

**Table I: Summary of Anti-LT-b-R mAbs**

		<u>HT29 Cytotoxicity</u>					
		Blocking	mAb	Soluble	Soluble		
Receptor							
mAb	cell	Receptor	Immobilized	mAb	mAb with	Band	mAb
<u>Name</u>	<u>Staining</u>	<u>Binding</u> <sup>a</sup>	<u>on Plastic</u> <sup>b</sup>	<u>alone</u>		<u>LTa1/b2</u>	
	<u>Precipitated</u> <sup>c</sup>	<u>Group</u> <sup>d</sup>					
10	BDA8	+++	+++	++	+/-	--- <sup>e</sup>	upper I
	AGH1	+++		+++	+/-	---	upper I
	BCG6	+++	++	+++	+/-	+/-	both II
15	BHA10	+++	+++	+/- <sup>e</sup>	+/-	+/-	nd II
	BKA11	+++	+/-	+++	-	+++ <sup>d</sup>	both III
	CDH10	+++		+++	+/-	+++	nd III
	CBE11	+++	nd	+++	+/-	-	both IV
20							

<sup>a</sup> Assay assessed whether antibody blocks binding of soluble receptor to activated II-23. nd = not done.

<sup>b</sup> Goat anti-mouse Fc coated plate, captured anti-receptor mAb, HT29s plus IFNg.

<sup>c</sup> Blocks

25 <sup>d</sup> Potentiates

<sup>e</sup> Variable, some partial inhibition in some assays, none in others.

<sup>f</sup> Receptor form precipitated using mAb plus KappaLock system.

<sup>g</sup> Groups were defined on the basis of the data in this table plus epitope mapping done using BIAcore technology.

**Table II Expression of LT $\beta$ R-Ig constructs in CHO cells cultured at different culture temperatures.**

<b>Construct</b>	<b>Fermentation Temperature °C</b>	<b>Expression mg/L<sup>a</sup></b>	<b>% Inactive Components<sup>b</sup></b>
<b>LT<math>\beta</math>R05</b>	<b>37</b>	<b>6</b>	<b>50</b>
	<b>32</b>	<b>12</b>	<b>17</b>
	<b>28</b>	<b>20</b>	<b>10</b>
<b>LT<math>\beta</math>R09</b>	<b>37</b>	<b>10</b>	<b>50</b>
	<b>32</b>	<b>-</b>	<b>-</b>
	<b>28</b>	<b>76</b>	<b>6</b>

5 <sup>a</sup> The expression level was assessed using Protein A affinity chromatography.

<sup>b</sup> The amount of inactive components present in the LT $\beta$ R-Ig preparation was assessed after Protein A affinity purification using the analytical HIC method.

**Table III. DME/HAM's F-12 Growth Media Supplements**

<b>Component</b>	<b>Amount in 1L growth media<sup>a</sup></b>
Fetal Bovine Serum	100 ml
Glucose	1.85 g
Ammonium bicarbonate	2.2 g
Streptomycin	140 mg
Gentamycin	50 mg
Ethanolamine (1 M stock)	0.1 ml
Lipoic acid	91.2 mg
Linoleic acid	38.4 mg
Triiodo-L-Thyronine	0.2 mg
Ex-Cyte VLE (Bayer)	1 ml
Bovine Insulin	10 mg
Bovine Transferrin	10 mg
Bovine Serum Albumin	50 mg
Pluronic F-68	1 g
Cysteine	82 mg
Methionine	34 mg
Serine	52 mg
Valine	105.6 mg
Glycine	50 mg
Aspartic Acid	24.4 mg
Proline	52.2 mg

<sup>a</sup> Components are mixed with the base media powder and the volume is then brought to 1L. The pH of the media is adjusted to 7.20 ñ 7.25 using 50% HCl.

## References

- Aggarwal, B. and Natarajan, K. (1996) *Eur. Cytokine Rev.* 7:93
- Alderson, M. R. et al. (1994) *Eur J Immunol* 24, 2219-27
- Ashkenazi, A. et al. (1991) *Proc Natl Acad Sci U S A* 88, 10535-9
- 5 Banner, D. W. et al (1993) *Cell* 73, 431-445
- Baum, P. R. et al. (1994) *Embo J* 13, 3992-4001
- Bazzoni, F. and Beutler, B. (1996) *New England J. Med.* 334:1717.
- Browning, J. L. et al. (1995) *J. Immunol.* 154, 33-46
- Browning, J. et al, (1996) *J. Exp. Med.* 183, 867-878
- 10 Browning, J.L. et al. (1996a) *J. Biol. Chem.* 271, 8618-8628
- Bucay, N. et al. (1998) *Genes and Development* 12:1260
- Chaplin, D. and Fu, Y-X. (1998) *Current Opinion in Immunology* 10, 289-297
- Chiceportiche, Y. et al (1997) *J. Biol. Chem.* 272, 32401-32410
- Corcoran, A. et al (1994) *Eur. J. Biochem.* 223, 831-840
- 15 Crowe, P. D. et al. (1994) *Science* 264, 707-10
- Eason, J. D. et al. (1996) *Transplantation* 61:224.
- Eggermont, A. M. et al. (1996) *J. Clin. Oncology* 14:2653
- Fanslow, W. C. et al. (1992) *J Immunol* 149, 655-60
- Feldmann, M. et al. (1997) *Ann. Immunol.* 64:283-350.
- 20 Goodwin, R. G. et al. (1993) *Cell* 73, 447-56
- Green, D. and Ware, C. F. (1997) *Proc. Natl. Acad. Sci USA* 94:5986
- Harrop, J.A., et al, (1998) *J. Biol. Chem.* 273:27548.
- Loetscher, H. et al. (1991) *J Biol Chem* 266, 18324-9
- Mackay, F. et al. (1998) *Gastroenterology* 115: 1484-1475
- 25 Mackay, F and Browning, J. (1998) *Nature* 395:26
- Mackay, F. et al. (1997) *Eur J Immunol* 27, 2033-42
- Marsters, S. et al (1992) *J. Biol. Chem.* 267, 5747-5750
- Mauri, D. N. et al. (1998) *Immunity* 8, 21-30
- Mohler, et al. (1993) *J Immunol* 151, 1548-61
- 30 Naismith, J. et al (1996) *J. Mol. Recognition* 9, 113-117
- Rennert, P. D. et al. (1996) *J Exp Med* 184, 1999-2006
- Rennert, P. D., Browning, J. L., and Hochman, P. S. (1997) *Int Immunol* 9, 1627-39



Simmonet, W. S. et al. (1997) *Cell* **89**:309.

Smith, C. A., Farrah, T., and Goodwin, R. G. (1994) *Cell* **76**, 959-62

Smith, C. A. et al. (1993) *Cell* **73**, 1349-60

Suda, T., Takahashi, T., Golstein, P., and Nagata, S. (1993) *Cell* **75**, 1169-78

5 Van Dullemen, H. M. et al. (1995) *Gastroenterology* **109**:129

Ware, C. F. et al. (1995) *Current topics in Microbiology and Immunology* **198**, 175-218

What is claimed is:

1. A method for the expression of high yields of active protein-Ig fusions comprising culturing a host transformed with DNA encoding a desired protein-Ig fusion in a culture system having a low temperature of about 27° C to about 35° C.
2. The method of claim 1 wherein the temperature is about 27°C to about 32° C.
3. The method of claim 3 wherein said transformed host is first cultured at a temperature above about 33° C for a period of time sufficient to allow growth of said host.
4. The method of claim 1 wherein said protein-Ig fusion comprises a member of the TNF receptor family.
5. The method of claim 3 wherein said TNF receptor family member is a lymphotoxin-β receptor, TNFR-55, HVEM or a fragment thereof.
6. The method of claim 1 further comprising the step of recovering active protein-Ig fusions from said culture system by hydrophobic interaction chromatography.
7. The method of claim 1 wherein said culture system comprises insect or bacterial cells.
8. An active protein-Ig fusion obtained by culturing a host transformed with DNA encoding the fusion in a culture system having a low temperature of about 27° C to about 35 ° C.
9. The fusion of claim 8 comprising a member of the TNF family.
10. The fusion of claim 9 comprising LT-β receptor, or a fragment thereof.
11. The fusion of claim 9 comprising HVEM, or a fragment thereof.
12. A method of making a pharmaceutical preparation comprising an active protein-Ig fusion said method comprising:
  - (a) culturing a host transformed with DNA encoding the protein-Ig fusion in a culture system having a low temperature of about 27° C to about 32 ° C, thereby expressing active protein-Ig fusions;
  - (b) recovering active protein-Ig fusions from said culture system; and
  - (c) combining the active protein-Ig fusions of step (b) with a pharmaceutically acceptable carrier.

13. The method of claim 12 wherein the protein-Ig fusion comprises a member of the TNF family, or a fragment thereof.
14. The method of claim 13 wherein the protein-Ig fusion comprises lymphotoxin- $\beta$  receptor or a fragment thereof.
- 5 15. The method of claim 13 wherein the protein-Ig fusion comprises HVEM, or a fragment thereof.
16. A pharmaceutical preparation obtained by
- (a) culturing a host transformed with DNA encoding the protein-Ig fusion in a culture system having a low temperature of about 27° C to about 32 ° C, thereby
- 10 expressing active protein-Ig fusions;
- (b) recovering active protein-Ig fusions from said culture system; and
- (c) combining the active protein-Ig fusions of step (b) with a pharmaceutically acceptable carrier.
17. The pharmaceutical preparation of claim 16 wherein the protein-Ig fusion comprises
- 15 a member of the TNF family.
18. The pharmaceutical preparation of claim 17 wherein the protein-Ig fusion comprises a lymphotoxin- $\beta$  receptor or a fragment thereof.
19. The pharmaceutical preparation of claim 17 wherein the protein-Ig fusion comprises HVEM, or a fragment thereof.
- 20 20. A method for the expression of high yields of active protein-Ig fusions comprising culturing yeast transformed with DNA encoding a desired protein-Ig fusion in a culture system having a low temperature of about 10° C to about 25° C.
21. The method of claim 20 wherein the temperature is about 15°C to about 20° C.
22. The method of claim 20 wherein said transformed host is first cultured at a
- 25 temperature above about 30° C for a period of time sufficient to allow growth of said host.
23. The method of claim 20 wherein said protein-Ig fusion comprises a member of the TNF receptor family.
24. The method of claim 23 wherein said TNF receptor family member is a
- 30 lymphotoxin- $\beta$  receptor or a fragment thereof.
25. The method of claim 20 further comprising the step of recovering active protein-Ig fusions from said culture system by hydrophobic interaction chromatography.

26. An active protein-Ig fusion obtained by culturing yeast transformed with DNA encoding the fusion in a culture system having a low temperature of about 10° C to about 25 ° C.
27. The fusion of claim 26 comprising a member of the TNF family.
- 5 28. The fusion of claim 27 comprising LT-β receptor, or a fragment thereof.
29. The fusion of claim 26 comprising HVEM, or a fragment thereof.
30. A pharmaceutical preparation comprising an active protein-Ig fusion having an Ig Fc domain and peptide chains, wherein the Ig Fc domain is altered thereby altering the rate of disulfide formation in the hinge region of said protein-Ig fusion.
- 10 31. The preparation of claim 30, wherein said Ig Fc domain is altered by replacing at least one cysteine residue with alanine.
32. A protein-Ig fusion comprising an Ig-Fc domain crosslinked to a peptide derived from the TNF family wherein at least one cysteine residue on the Ig-Fc domain is replaced with alanine.
- 15 33. The protein-Ig fusion of claim 32 wherein said peptide is derived from a lymphotoxin-β receptor.
34. A method of making a protein-Ig fusion comprising an Ig Fc domain crosslinked to a peptide derived from the TNF receptor family by mutagenizing at least one cysteine residue to an alanine, thereby increasing the yield of active forms of fusion expressed.
- 20 35. The method of claim 34 wherein said peptide is LTBR, and the cysteines at positions 101 and 108 are mutagenized to alanines.
36. An LTBR-Ig fusion protein comprising alanine at positions 101 and 108 of the LTBR peptide.

# Receptor-ImmunoglobulinFc Chimeric Proteins Schematic Illustration




FIG. 1

Possible Nature of the LTBR-Ig  
"Live/Dead" Problem




FIG. 2






FIG. 3




FIG. 4

BEST AVAILABLE COPY

FACS ANALYSIS OF AG-H1-5 PURIFIED  
UPPER AND LOWER BANDS ON PMA  
(50ng/mL) ACTIVATED II-23 CELLS




FIG. 5A

FIG. 5B





FIG. 5C




FIG. 6




FIG. 7




FIG. 8




FIG. 9

8/11



FIG. 10




FIG. 11A






FIG. 11C




FIG. 11B

37 C (4593 RU)  
Ligand = human LIGHT




FIG. 12A

32 C (4760 RU)  
Ligand = human LIGHT




FIG. 12B

28 C (4808 RU)  
Ligand = human LIGHT




FIG. 12C

10/11

37 C (4593 RU)  
Ligand = human L1a




FIG. 12D

32 C (4760 RU)  
Ligand = human L1a




FIG. 12E

28 C (4808 RU)  
Ligand = human L1a




FIG. 12F

11/11

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/29873

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N5/10 C12N1/19 C12N1/21 C07K19/00 A61K38/00  
 //C07K14/705,C07K14/525

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DEGLI-ESPOSTI M A ET AL: "Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells." JOURNAL OF IMMUNOLOGY, (1997 FEB 15) 158 (4) 1756-62. , XP002141941 page 1757, left-hand column, line 6 - line 28	1-10, 12-14, 16-18, 20-28
Y	---	11,15, 19,29-36
Y	WO 97 04658 A (NORTH-WESTERN UNIVERSITY) 13 February 1997 (1997-02-13) page 2, line 30 - line 35; claims 1-27 --- -/--	11,15, 19,29



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

6 July 2000

Date of mailing of the international search report

24/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Le Flao, K

BEST AVAILABLE COPY

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/29873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	RUDIHOFF S ET AL: "Functional antibody lacking a variable-region disulfide bridge." PROCEEDINGS OF NATIONAL ACADEMY OF SCIENCE OF THE USA (1986) 83 7875-8, XP002142019 abstract ---	30-36
A	US 5 605 690 A (JACOBS ET AL) 25 February 1997 (1997-02-25) claims 4,6 ---	30-36
A	EP 0 496 973 A (BIO-TECHNOLOGY GENERAL CORPORATION) 5 August 1992 (1992-08-05) claim 19 ---	30-36
A	WILLIAMS R ET AL: "Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4." IMMUNOLOGY (1995) 84 (3) 433-9, XP000494802 abstract ---	1-36
A	WO 98 17313 A (BIOGEN) 30 April 1998 (1998-04-30) claims 1-50 ---	1-36
A	EP 0 608 532 A (AMERICAN CYANAMID COMPANY) 3 August 1994 (1994-08-03) claim 1 ---	20-29
P,X	WO 99 53059 A (GENENTECH) 21 October 1999 (1999-10-21) claims 1-33 ---	1,12
P,X	HUDE T ET AL: "Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium." GENE THERAPY, (1999 MAY) 6 (5) 939-43. , XP000915210 abstract page 942, left-hand column, line 6 - line 11 -----	1,12

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/29873

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9704658	A	13-02-1997	NONE	
US 5605690	A	25-02-1997	US 5395760 A	07-03-1995
			AU 670125 B	04-07-1996
			AU 4920993 A	12-04-1994
			CA 2123593 A	31-03-1994
			EP 0620739 A	26-10-1994
			JP 7504203 T	11-05-1995
			NO 941780 A	15-07-1994
			NZ 256293 A	24-06-1997
			WO 9406476 A	31-03-1994
			AT 131871 T	15-01-1996
			DE 69024291 D	01-02-1996
			DE 69024291 T	31-10-1996
			DK 418014 T	22-01-1996
			EP 0418014 A	20-03-1991
			ES 2080809 T	16-02-1996
			GR 3019333 T	30-06-1996
			IE 63505 B	03-05-1995
			JP 2960039 B	06-10-1999
			JP 10191986 A	28-07-1998
			JP 2721745 B	04-03-1998
			JP 3133382 A	06-06-1991
			MX 9203660 A	01-07-1992
			NZ 235148 A	23-12-1991
			US 5712155 A	27-01-1998
			US 5945397 A	31-08-1999
			AU 630497 B	29-10-1992
			AU 6178190 A	08-04-1991
			CA 2065346 A	06-03-1991
			NO 920862 A	04-05-1992
			WO 9103553 A	21-03-1991
			DD 297664 A	16-01-1992
			ZA 9007072 A	30-10-1991
EP 0496973	A	05-08-1992	AT 163045 T	15-02-1998
			AU 662493 B	07-09-1995
			AU 8830091 A	04-06-1992
			CA 2056467 A,C	31-05-1992
			DE 69128877 D	12-03-1998
			DE 69128877 T	18-06-1998
			DK 496973 T	04-05-1998
			ES 2112847 T	16-04-1998
			FI 915654 A	31-05-1992
			GR 3026761 T	31-07-1998
			HU 215947 B	29-03-1999
			JP 5105634 A	27-04-1993
			KR 193005 B	15-06-1999
			NO 301235 B	29-09-1997
			NZ 240718 A	28-10-1996
			NZ 260103 A	28-10-1996
			PT 99648 A,B	30-10-1992
			SG 49702 A	15-06-1998
			US 5548068 A	20-08-1996
			ZA 9109453 A	26-08-1992
WO 9817313	A	30-04-1998	AU 5089698 A	15-05-1998
			BG 103416 A	31-01-2000

BEST AVAILABLE COPY



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/29873

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9817313 A		BR 9712670 A	19-10-1999
		CN 1237910 A	08-12-1999
		CZ 9901428 A	14-07-1999
		EP 0954333 A	10-11-1999
		NO 991926 A	25-06-1999
		PL 332972 A	25-10-1999
EP 0608532 A	03-08-1994	US 5691196 A	25-11-1997
		CA 2112527 A	01-07-1994
		JP 6292580 A	21-10-1994
		US 5700682 A	23-12-1997
		US 5714595 A	03-02-1998
		US 5700650 A	23-12-1997
WO 9953059 A	21-10-1999	AU 3641699 A	01-11-1999

BEST AVAILABLE COPY